1887
  1. Home
  2. Eurosurveillance
  3. Volume 29, Issue 13, 28/Mar/2024
  4. Article
Research Open Access
Like 0
Download

Abstract

Background

Scarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants.

Aim

We aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1/BA.2 infection and investigate potential biases.

Methods

This European test-negative multicentre study tested primary care patients with acute respiratory symptoms for SARS-CoV-2 in the BA.1/BA.2-dominant period. We estimated PS and booster VE among adults and adolescents (PS only) for all products combined and for Comirnaty alone, by time since vaccination, age and chronic condition. We investigated potential bias due to correlation between COVID-19 and influenza vaccination and explored effect modification and confounding by prior SARS-CoV-2 infection.

Results

Among adults, PS VE was 37% (95% CI: 24–47%) overall and 60% (95% CI: 44–72%), 43% (95% CI: 26–55%) and 29% (95% CI: 13–43%) < 90, 90–179 and ≥ 180 days post vaccination, respectively. Booster VE was 42% (95% CI: 32–51%) overall and 56% (95% CI: 47–64%), 22% (95% CI: 2–38%) and 3% (95% CI: −78% to 48%), respectively. Primary series VE was similar among adolescents. Restricting analyses to Comirnaty had little impact. Vaccine effectiveness was higher among older adults. There was no signal of bias due to correlation between COVID-19 and influenza vaccination. Confounding by previous infection was low, but sample size precluded definite assessment of effect modification.

Conclusion

Primary series and booster VE against symptomatic infection with BA.1/BA.2 ranged from 37% to 42%, with similar waning post vaccination. Comprehensive data on previous SARS-CoV-2 infection would help disentangle vaccine- and infection-induced immunity.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2024.29.13.2300403
2024-03-28
2024-11-21
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2024.29.13.2300403
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/29/13/eurosurv-29-13_5.html?itemId=/content/10.2807/1560-7917.ES.2024.29.13.2300403&mimeType=html&fmt=ahah

References

  1. European Medicines Agency (EMA). Authorised COVID-19 vaccines. Amsterdam: EMA. [Accessed: 21 Mar 2024]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised
  2. Kissling E, Hooiveld M, Martínez-Baz I, Mazagatos C, William N, Vilcu AM, et al. Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021. Euro Surveill. 2022;27(21):2101104.  https://doi.org/10.2807/1560-7917.ES.2022.27.21.2101104  PMID: 35620997 
  3. Halloran ME, Longini IM, Struchiner CJ. Design and analysis of vaccine studies. New York: Springer; 2010. 387 p. https://doi.org/10.1007/978-0-387-68636-3
  4. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical basis of the test-negative study design for assessment of influenza vaccine effectiveness. Am J Epidemiol. 2016;184(5):345-53.  https://doi.org/10.1093/aje/kww064  PMID: 27587721 
  5. Doll MK, Pettigrew SM, Ma J, Verma A. Effects of confounding bias in coronavirus disease 2019 (COVID-19) and influenza vaccine effectiveness test-negative designs due to correlated influenza and COVID-19 vaccination behaviors. Clin Infect Dis. 2022;75(1):e564-71.  https://doi.org/10.1093/cid/ciac234  PMID: 35325923 
  6. Grochowska M, Ratajczak A, Zdunek G, Adamiec A, Waszkiewicz P, Feleszko W. A comparison of the level of acceptance and hesitancy towards the influenza vaccine and the forthcoming COVID-19 vaccine in the medical community. Vaccines (Basel). 2021;9(5):475.  https://doi.org/10.3390/vaccines9050475  PMID: 34066790 
  7. Li M, Luo Y, Watson R, Zheng Y, Ren J, Tang J, et al. Healthcare workers’ (HCWs) attitudes and related factors towards COVID-19 vaccination: a rapid systematic review. Postgrad Med J. 2023;99(1172):520-8.  https://doi.org/10.1136/postgradmedj-2021-140195  PMID: 37319159 
  8. Wang Q, Yang L, Jin H, Lin L. Vaccination against COVID-19: A systematic review and meta-analysis of acceptability and its predictors. Prev Med. 2021;150:106694.  https://doi.org/10.1016/j.ypmed.2021.106694  PMID: 34171345 
  9. Ioannidis JPA. Factors influencing estimated effectiveness of COVID-19 vaccines in non-randomised studies. BMJ Evid Based Med. 2022;27(6):324-9.  https://doi.org/10.1136/bmjebm-2021-111901  PMID: 35338091 
  10. Lewnard JA, Tedijanto C, Cowling BJ, Lipsitch M. Measurement of vaccine direct effects under the test-negative design. Am J Epidemiol. 2018;187(12):2686-97.  https://doi.org/10.1093/aje/kwy163  PMID: 30099505 
  11. Powell AA, Kirsebom F, Stowe J, Ramsay ME, Lopez-Bernal J, Andrews N, et al. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021–March, 2022: a national, observational, test-negative, case-control study. Lancet Infect Dis. 2023;23(4):435-44. PMID: 36436536 
  12. Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, et al. Estimated effectiveness of COVID-19 vaccines against omicron or delta symptomatic infection and severe outcomes. JAMA Netw Open. 2022;5(9):e2232760.  https://doi.org/10.1001/jamanetworkopen.2022.32760  PMID: 36136332 
  13. Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ. 2021;374:n1943.  https://doi.org/10.1136/bmj.n1943  PMID: 34417165 
  14. Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28(2):202-21.  https://doi.org/10.1016/j.cmi.2021.10.005  PMID: 34715347 
  15. Mohammed H, Pham-Tran DD, Yeoh ZYM, Wang B, McMillan M, Andraweera PH, et al. A systematic review and meta-analysis on the real-world effectiveness of COVID-19 vaccines against infection, symptomatic and severe COVID-19 disease caused by the Omicron variant (B.1.1.529). Vaccines (Basel). 2023;11(2):224.  https://doi.org/10.3390/vaccines11020224  PMID: 36851102 
  16. Kissling E, Pozo F, Martínez-Baz I, Buda S, Vilcu AM, Domegan L, et al. Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021-2022 I-MOVE primary care multicentre study. Influenza Other Respir Viruses. 2023;17(1):e13069.  https://doi.org/10.1111/irv.13069  PMID: 36702797 
  17. Kissling E, Hooiveld M, Sandonis Martín V, Martínez-Baz I, William N, Vilcu AM, et al. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. Euro Surveill. 2021;26(29):2100670.  https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670  PMID: 34296676 
  18. Valenciano M, Ciancio BC. on behalf of the I-MOVE study team C. I-MOVE: a European network to measure the effectiveness of influenza vaccines. Euro Surveill. 2012;17(39):20281.  https://doi.org/10.2807/ese.17.39.20281-en  PMID: 23041022 
  19. European Commission. Commission Implementing Decision (EU) 2018/945 of 22 June 2018 on the communicable diseases and related special health issues to be covered by epidemiological surveillance as well as relevant case definitions (Text with EEA relevance.). Official Journal of the European Union. Luxembourg: Publications Office of the European Union 6.7.2018:L 170/1. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX%3A32018D0945&from=EN%29
  20. European Centre for Disease Prevention and Control (ECDC). Data on SARS-CoV-2 variants in the EU/EEA. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/en/publications-data/data-virus-variants-covid-19-eueea
  21. Firth D. Bias reduction of maximum likelihood estimates. Biometrika. 1993;80(1):27-38.  https://doi.org/10.1093/biomet/80.1.27 
  22. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373-9.  https://doi.org/10.1016/S0895-4356(96)00236-3  PMID: 8970487 
  23. Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. Effects of previous infection and vaccination on symptomatic Omicron infections. N Engl J Med. 2022;387(1):21-34.  https://doi.org/10.1056/NEJMoa2203965  PMID: 35704396 
  24. Tartof SY, Xie F, Yadav R, Wernli KJ, Martin ET, Belongia EA, et al. Prior SARS-CoV-2 infection and COVID-19 vaccine effectiveness against outpatient illness during widespread circulation of SARS-CoV-2 Omicron variant, US Flu VE Network. Epidemiology. 2023.
  25. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the omicron (b.1.1.529) variant. N Engl J Med. 2022;386(16):1532-46.  https://doi.org/10.1056/NEJMoa2119451  PMID: 35249272 
  26. Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022;28(5):1063-71.  https://doi.org/10.1038/s41591-022-01753-y  PMID: 35189624 
  27. Kim SS, Chung JR, Talbot HK, Grijalva CG, Wernli KJ, Kiniry E, et al. Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron- and Delta-related outpatient illness among adults, October 2021-February 2022. Influenza Other Respir Viruses. 2022;16(6):975-85.  https://doi.org/10.1111/irv.13029  PMID: 36825251 
  28. Kahn R, Schrag SJ, Verani JR, Lipsitch M. Identifying and alleviating bias due to differential depletion of susceptible people in postmarketing evaluations of COVID-19 vaccines. Am J Epidemiol. 2022;191(5):800-11.  https://doi.org/10.1093/aje/kwac015  PMID: 35081612 
  29. Wong KLM, Gimma A, Coletti P, CoMix Europe Working GroupFaes C, Beutels P, et al. Social contact patterns during the COVID-19 pandemic in 21 European countries - evidence from a two-year study. BMC Infect Dis. 2023;23(1):268.  https://doi.org/10.1186/s12879-023-08214-y  PMID: 37101123 
  30. Tsang NNY, So HC, Cowling BJ, Leung GM, Ip DKM. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study. Lancet Infect Dis. 2023;23(4):421-34. PMID: 36521506 
  31. Castelli JM, Rearte A, Olszevicki S, Voto C, Del Valle Juarez M, Pesce M, et al. Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study. BMJ. 2022;379:e073070.  https://doi.org/10.1136/bmj-2022-073070  PMID: 36450402 
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Charlotte+Lani%C3%A8ce+Delaunay&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Lanièce Delaunay Charlotte</a>, <a href="/search?value1=Iv%C3%A1n+Mart%C3%ADnez-Baz&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Martínez-Baz Iván</a>, <a href="/search?value1=No%C3%A9mie+S%C3%A8ve&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Sève Noémie</a>, <a href="/search?value1=Lisa+Domegan&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Domegan Lisa</a>, <a href="/search?value1=Clara+Mazagatos&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mazagatos Clara</a>, <a href="/search?value1=Silke+Buda&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Buda Silke</a>, <a href="/search?value1=Adam+Meijer&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Meijer Adam</a>, <a href="/search?value1=Irina+Kislaya&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kislaya Irina</a>, <a href="/search?value1=Catalina+Pascu&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pascu Catalina</a>, <a href="/search?value1=AnnaSara+Carnahan&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Carnahan AnnaSara</a>, <a href="/search?value1=Beatrix+Oroszi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Oroszi Beatrix</a>, <a href="/search?value1=Maja+Ili%C4%87&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ilić Maja</a>, <a href="/search?value1=Marine+Maurel&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Maurel Marine</a>, <a href="/search?value1=Aryse+Melo&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Melo Aryse</a>, <a href="/search?value1=Virginia+Sandonis+Mart%C3%ADn&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Sandonis Martín Virginia</a>, <a href="/search?value1=Camino+Trobajo-Sanmart%C3%ADn&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Trobajo-Sanmartín Camino</a>, <a href="/search?value1=Vincent+Enouf&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Enouf Vincent</a>, <a href="/search?value1=Adele+McKenna&option1=author&noRedirect=true" class="nonDisambigAuthorLink">McKenna Adele</a>, <a href="/search?value1=Gloria+P%C3%A9rez-Gimeno&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pérez-Gimeno Gloria</a>, <a href="/search?value1=Luise+Goerlitz&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Goerlitz Luise</a>, <a href="/search?value1=Marit+de+Lange&option1=author&noRedirect=true" class="nonDisambigAuthorLink">de Lange Marit</a>, <a href="/search?value1=Ana+Paula+Rodrigues&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Rodrigues Ana Paula</a>, <a href="/search?value1=Mihaela+Lazar&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Lazar Mihaela</a>, <a href="/search?value1=Neus+Latorre-Margalef&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Latorre-Margalef Neus</a>, <a href="/search?value1=Gerg%C5%91+T%C3%BAri&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Túri Gergő</a>, <a href="/search?value1=Jes%C3%BAs+Castilla&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Castilla Jesús</a>, <a href="/search?value1=Alessandra+Falchi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Falchi Alessandra</a>, <a href="/search?value1=Charlene+Bennett&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bennett Charlene</a>, <a href="/search?value1=Virtudes+Gallardo&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Gallardo Virtudes</a>, <a href="/search?value1=Ralf+D%C3%BCrrwald&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Dürrwald Ralf</a>, <a href="/search?value1=Dirk+Eggink&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Eggink Dirk</a>, <a href="/search?value1=Raquel+Guiomar&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Guiomar Raquel</a>, <a href="/search?value1=Rodica+Popescu&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Popescu Rodica</a>, <a href="/search?value1=Maximilian+Riess&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Riess Maximilian</a>, <a href="/search?value1=Judit+Krisztina+Horv%C3%A1th&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Horváth Judit Krisztina</a>, <a href="/search?value1=Itziar+Casado&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Casado Itziar</a>, <a href="/search?value1=M%C2%AA+del+Carmen++Garc%C3%ADa&option1=author&noRedirect=true" class="nonDisambigAuthorLink">García Mª del Carmen </a>, <a href="/search?value1=Mari%C3%ABtte+Hooiveld&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hooiveld Mariëtte</a>, <a href="/search?value1=Ausenda+Machado&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Machado Ausenda</a>, <a href="/search?value1=Sabrina+Bacci&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bacci Sabrina</a>, <a href="/search?value1=Marlena+Kaczmarek&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kaczmarek Marlena</a>, <a href="/search?value1=Esther+Kissling&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kissling Esther</a>, <a href="/search?value1=on+behalf+of+the+European+Primary+Care+Vaccine+Effectiveness+Group&option1=author&noRedirect=true" class="nonDisambigAuthorLink">on behalf of the European Primary Care Vaccine Effectiveness Group</a></span>. COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022. <a href="/content/ecdc">Euro Surveill.</a> 2024;29(13):pii=2300403. <a href="https://doi.org/10.2807/1560-7917.ES.2024.29.13.2300403" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2024.29.13.2300403</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 28 Jul 2023;&nbsp;&nbsp; <span class="generated">Accepted</span>: 14 Dec 2023 </span> </p>
/content/10.2807/1560-7917.ES.2024.29.13.2300403
/content/10.2807/1560-7917.ES.2024.29.13.2300403
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error